NCM
JAZZ icon

Next Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Next Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-41
Closed -$6K – 526
2019
Q2 		$6K Buy
+41
New +$5.51K ﹤0.01% 584

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Next Capital Management's JAZZ Position: Q3 2019 in Review

Next Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2019, closing a stake of 41 shares — an estimated $6K sold.

Next Capital Management first reported a position in JAZZ in Q2 2019 and held it in 1 quarter. The position peaked at $6K in Q2 2019. 406 funds tracked by Wall St. Rank hold JAZZ as of Q3 2019.

  • Next Capital Management reported no remaining Jazz Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Next Capital Management sold 41 Jazz Pharmaceuticals shares in Q3 2019, an estimated $6K.
  • Next Capital Management first reported a position in Jazz Pharmaceuticals in Q2 2019 and held it in 1 quarter.
  • Next Capital Management's Jazz Pharmaceuticals position peaked at $6K in Q2 2019.
  • 406 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2019.

Based on Next Capital Management's 13F filing for Q3 2019, filed 12 Nov 2019.